The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily

HIV Medicine

Volumn 6, Issue 3, 2005, Pages 151-154

  Tung, Mun Yee ^a   Mandalia, S ^a   Bower, M ^a   Gazzard, B ^a   Nelson, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy toxicity; Drug interaction; Highly active antiretroviral therapy; Treatment simplification

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; GLUCOSE; LACTIC ACID; PANCREAS ENZYME; PHOSPHATE; TENOFOVIR;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPOPHOSPHATEMIA; LACTIC ACIDOSIS; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PANCREAS DISEASE; PANCREAS INSUFFICIENCY; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT FAILURE; VIRAL LOAD;

EID: 19644386314     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00279.x     Document Type: Article

References (7)

1. Damle BD, Yan JH, Behr D. Effect of food on oral availability of didanosine from encapsulated enteric-coated beads. J Clin Pharm 2002; 42: 419-427.
2. Kearny BP, Flaherty J, Wolf J et al. Coadministration of tenofovir DF and didanosine: pharmacokinetic drug-drug interaction and safety evaluation. European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece, October 2001 [Poster 172].
3. Kaul S, Damle B, Bassi K et al. Pharmacokinetic evaluation of reduced doses of didanosine enteric coated (ddI EC) in combination with tenofovir disoproxil fumerate (TDF) and food for once daily antiretroviral regimen. International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, March 2003 [Poster 8.1].
4. Negredo E, Molto J, Burger D et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18: 459-463.
5. Martinez E, Milinkovic A, de Lazzari E et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364: 65-67.
6. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36: 1802-1085.
7. Winston A, Mandalia S, Pillay D et al. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir naïve patients. AIDS 2002; 16: 2087-2089.